Table 1.

Arrhythmia prevalence in bortezomib-treated CASQ2 mutant mice.

Genotype	N (mice)	Sinus rate (beats/min, mean ± SD)	Rest PVC	Rest VT	Stress PVC	Stress VT	Epi PVC	Epi VT
KO Baseline	4	448 ± 3	4	4	4	4	4	4
KO Bortezomib	4	507 ± 31	4	4	4	4	4	4
D307H Baseline	4	495 ± 144	4	3	4	4	4	4
D307H Bortezomib	4	557 ± 51	1	0*	4	1*	4	4

Mutant mice (D307H and KO) were treated with 4 injections of bortezomib [1 μg/g] IV for 11 days. Then, Mice were subjected to telemetric heart rhythm monitoring and provocation testing on day 11, 1 h after the last injection (see Section 2). Results were compared to arrhythmia incidence in the same mice subjected to the same provocation testing prior to bortezomib therapy. A decrease in arrhythmia incidence was observed in D307H mice following bortezomib treatment. However, there was no protection of bortezomib against arrhythmia after epinephrine [0.5 μg/g] stimulation. There was no effect on arrhythmia in the KO group.

Numbers represent number of mice having a given type of arrhythmia. Abbreviations: Epi: epinephrine; PVC: premature ventricular contraction, VT, ventricular tachycardia; D307H, CASQ2^D307H/D307H; CASQ2^Δ/Δ, KO; wild type, WT. p <0.05 *